Previous 10 | Next 10 |
Amarin Corp. ( NASDAQ: AMRN ) on Wednesday said it will announce the date of a special meeting of shareholders "in due course" after its largest shareholder on Tuesday demanded the ousting of the board chairman and adding representatives it backs. Sarissa Capital Management has be...
DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) (“Amarin” or the “Company”) today confirmed receipt of a requisition by Sarissa Capital Management LP (“Sarissa”) to convene a General Meeting of...
Cantor Fitzgerald issued positive remarks on Amarin Corporation ( NASDAQ: AMRN ) after the Ireland-based biotech preannounced its Q4 and 2022 financials on Tuesday, exceeding Wall Street and the firm’s own forecasts for revenue. The analyst Louise Chen points out that Amarin ( ...
The following slide deck was published by Amarin Corporation plc in conjunction with this event. For further details see: Amarin JPM Presentation 2023
Amarin Corporation plc (AMRN) 41st Annual J.P. Morgan Healthcare Conference January 10, 2023 8:15 p.m. ET Company Participants Karim Mikhail - President and Chief Executive Officer Tom Reilly - Chief Financial Officer Presentation [Call Starts Abruptly] -- in E...
Sarissa Capital Management, Amarin Corp.'s ( NASDAQ: AMRN ) largest shareholder, is calling for a special meeting of shareholders to remove the current board chairman and add its backed representatives. Amarin ( AMRN ) is up ~19% in Tuesday afternoon terading. Sarissa said...
Sarissa believes current board lacks any remaining credibility for representing shareholders Sarissa is astonished that Amarin board refuses to add shareholder representatives Sarissa Capital Management LP (“Sarissa”) today made the following statement on Amarin Co...
Amarin Corporation ( NASDAQ: AMRN ), the maker of fish oil-derived therapy Vascepa/Vazkepa, preannounced its Q4 and 2022 financials on Tuesday, reporting the fourth consecutive quarter of U.S. revenue stabilization despite additional generic competition. Citing early unaudited financi...
-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European Reimbursements -- -- Amarin to Present at 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023 -- DUBLIN, Ireland and BRIDG...
-- Dr. Stewart Brings More Than 30 Years of Cardiometabolic Academic and Industry Experience to Amarin’s Board –- - - Ongoing Board Refreshment Program Has Led to Approximately 70% New Independent Directors Named to the Board Over the Last 12 Months -- DUBLIN, Ir...
News, Short Squeeze, Breakout and More Instantly...
Amarin Corporation plc Company Name:
AMRN Stock Symbol:
NASDAQ Market:
Amarin Corporation plc Website:
-- Portuguese Ministry of Health approves VAZKEPA® (icosapent ethyl) for national reimbursement to reduce the risk of cardiovascular (CV) events in patients with established cardiovascular disease (CVD) 1 -- -- Approval marks eighth national reimbursement of VAZKEPA®...
DUBLIN and BRIDGEWATER, N.J., July 17, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with Aaron Berg, President & CEO, and members of Amarin’s senior management team to discuss its second quarter 2024 results followed ...
-- VASCEPA Approved by the National Medical Products Administration (NMPA) To Reduce the Risk of Cardiovascular Events as an Adjunct to Statin Therapy in Adult Patients with Elevated Triglyceride (TG) Levels (≥150 mg/dL) and Other High-Risk Characteristics as Studied in REDUCE-IT -- ...